European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - bortezomib - multiple myeloma - antineoplastic agents - bortezomib sun as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib sun in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib sun in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib sun in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - zoledronic acid monohydrate - solution for infusion - 50microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - codeine phosphate - oral tablet - 15mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - terlipressin acetate - solution for injection - 120microgram/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - isotretinoin - capsule, soft - 10 milligram(s) - isotretinoin

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - isotretinoin - capsule, soft - 20 milligram(s) - isotretinoin

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 0.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extensiona and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 1 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 2 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Ireland - English - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 10 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.